2 weeks ago, we provided information on the Sensonics implantable CGM. Now, we have another implantable CGM that is in development. GlySens is developing a truly long-term continuous glucose monitoring system (expected life is one year or longer, demonstrated up to 18 months in preclinical studies) intended to dramatically improve the lives of people with diabetes. The basic system is comprised of two elements: (1) the fully implanted sensor (designed for long operational life) and (2) an external receiver with monitor. The external receiver is designed to offer a convenient means for continuous, at-a-glance glucose display, recording, and alerts regarding hypo- or hyperglycemic glucose excursions.The GlySens long-term ICGM System needs only a brief outpatient procedure to insert the sensors, and then is designed to work continuously, for an expected period of 12-18 months, with only occasional need for calibration anticipated. Other continuous glucose monitor needle-sensor approaches must be replaced every 3-7 days and require frequent calibration during use. What makes this system different is that the implant contains two independent detectors: the first measures glucose through a specific chemical reaction involving glucose and oxygen, which is monitored by an electrochemical “main” detector; the second is a “reference” detector that monitors background tissue oxygen levels. The system’s electronic circuitry automatically determines glucose levels by computing the difference between the signals from these two detectors. This approach is employed to reduce effects of secondary factors such as temperature and blood flow in the surrounding tissues and effects due to the body’s normal mild encapsulation response to the implant.